Septerna (SEPN) Stock Price, News & Analysis

Company Overview

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body. Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately one-third of all U.S. Food and Drug Administration (FDA) approved drugs, representing approximately 500 products with combined global revenue of approximately $125 billion in 2023. Despite the pharmacological and commercial success of GPCR-targeted agents, about 75% of potential GPCR therapeutic targets remain undrugged and, for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. Each step in GPCR activation involves subtle conformational changes that have been historically challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the state-of-the-art technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug discovery, particularly the development of novel oral small molecules, such as agonists (which activate GPCR signaling) for peptide GPCRs and allosteric modulators (which either increase or decrease the degree of GPCR activation by endogenous ligands). Our proprietary Native Complex Platform™ replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging our platform, we conduct GPCR oral small molecule drug discovery using an industrialized and iterative structure-based drug design approach for a diverse collection of GPCR targets. Our Native Complex PlatformTM is designed to enable us to target specific GPCRs, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists (which inhibit GPCR signaling), and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects. We are advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline, is focused initially on three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. We intend to evaluate opportunities in other major therapeutic areas, such as neurology, women's health, cardiovascular, and respiratory disease. --- Leveraging our team, scientific and technical advisors, and our proprietary Native Complex Platform™, we aim to be a leader in the development of oral GPCR-targeted medicines for patients with significant unmet needs. We were incorporated under the laws of the State of Delaware in December 2019 under the name GPCR NewCo, Inc. and changed our name to Septerna, Inc. in June 2021. Our principal executive offices are located at 250 East Grand Avenue, South San Francisco, California.

Key Stats

• Today's Range: $27.93 to $29.89
• 50-Day Range: $23.09 to $28.36
• 52-Week Range: $9.05 to $32.63
• Volume: 346,804 shs
• Average Volume: 329,525 shs
• Market Capitalization: $1.28 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.13
• Consensus Rating: Moderate Buy

Septerna Stock Analysis - MarketRank™

Septerna scored higher than 57% of companies evaluated by MarketBeat, and ranked 346th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Septerna has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 7 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Septerna has a consensus price target of $43.13, representing about 52.1% upside from its current price of $28.36.

Amount of Analyst Coverage

Septerna has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Septerna are expected to decrease in the coming year, from ($1.61) to ($2.46) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Septerna is -35.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Septerna is -35.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Septerna has a P/B Ratio of 3.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.81% of the float of Septerna has been sold short.

Short Interest Ratio / Days to Cover

Septerna has a short interest ratio ("days to cover") of 5.44.

Change versus previous month

Short interest in Septerna has recently decreased by 15.86%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Septerna does not currently pay a dividend.

Dividend Growth

Septerna does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for SEPN on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Septerna to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Septerna insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,077,089.00 in company stock.

Percentage Held by Insiders

4.30% of the stock of Septerna is held by insiders.

Percentage Held by Institutions

Septerna has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 5/25/2026
• Next Earnings (Estimated): 8/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SEPN
• Previous Symbol: NASDAQ:SEPN
• CIK: 1984086
• Web: N/A
• Phone: (650) 338-3533
• Fax: N/A
• Employees: N/A
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Septerna: $43.13
• High Price Target: $60.00
• Low Price Target: $35.00
• Potential Upside/Downside: +52.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.81)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$48.88 million
• Net Margins: -49.88%
• Pretax Margin: -49.40%
• Return on Equity: -12.72%
• Return on Assets: -8.87%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.71
• Quick Ratio: 4.71

Sales & Book Value

• Annual Sales: $45.95 million
• Price / Sales: 27.82
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.40 per share
• Price / Book: 3.38

Miscellaneous

• Outstanding Shares: 45,080,000
• Free Float: 43,138,000
• Market Cap: $1.28 billion
• Optionable: N/A
• Beta: 2.21